Overview

Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer

Status:
Unknown status

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess efficacy and safety of docetaxel alone, docetaxel plus cisplatin, and docetaxel plus S-1 in patients with metastatic gastric cancer after failing 1st line chemotherapy with cisplatin plus S-1 or capecitabine

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Center, Korea

Collaborators:

Chungbuk National University Hospital
Gachon University Gil Medical Center
Seoul National University Bundang Hospital

Treatments:

Cisplatin
Docetaxel